We are analyzing https://link.springer.com/article/10.1007/s10555-024-10219-1.

Title:
CAR T-cell therapy to treat multiple myeloma: current state and future directions | Cancer and Metastasis Reviews
Description:
Chimeric antigen receptor (CAR) T-cell therapy represents a transformative advancement in treating relapsed or refractory multiple myeloma (MM) in both early- and late-line settings. MM, a plasma cell malignancy, traditionally requires ongoing complex drug regimens, posing significant burdens on patients. In contrast, CAR T-cell therapy offers a one-time treatment option without the need for continuous maintenance therapy. CAR T-cell therapy leverages engineered T-cells to target specific antigens on tumor cells, leading to their elimination. Current approved therapies target B-cell maturation antigen (BCMA); new targets are under investigation, such as G-protein-coupled receptor class C group 5 member D (GPRC5D). Despite its efficacy, CAR T-cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS), necessitating careful management. The review will provide an overview of the design and manufacturing of CAR T-cells and current FDA indications, as well as challenges and future directions of CAR-T therapy for MM treatment.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be making money, but it's not detectable how they're doing it.

Keywords {🔍}

pubmed, article, google, scholar, myeloma, cas, multiple, therapy, car, central, cell, antigen, blood, journal, cells, tcell, chimeric, receptor, patients, cancer, clinical, relapsed, nature, relapsedrefractory, refractory, medicine, oncology, cart, phase, study, maturation, results, current, lymphoma, efficacy, research, mikkilineni, bcell, disease, reviews, review, treatment, target, ciltacabtagene, human, cellular, berdeja, idecabtagene, vicleucel, autoleucel,

Topics {✒️}

b-cell maturation antigen g-protein-coupled receptor class month download article/chapter protein-coupled receptor class protein–coupled receptor class bcma-car t-cell treatment t-cell therapy represents car t-cell therapy car-t-cell therapy adoptive t-cell therapy cell maturation antigen prior bcma-targeted therapy biepitopic car t-targeting chimeric antigen receptor fully human heavy-chain chimeric antigen receptors rapid anti-myeloma activity antigen-independent macrophage response pathogen-specific humoral immunity allogeneic bcma-targeting car long-term car19 responders car t-cell toxicity plasma cell malignancy plasma cell disorders matching-adjusted indirect comparison cell therapy directed t-cell therapy lenalidomide-refractory multiple myeloma bcma-targeting therapies antigen recognition domains anti-infective therapy relapsed/refractory multiple myeloma cell therapy cc-98633/bms-986354 antigen-binding domain full article pdf t-cell phenotypes open-label study anti-bcma car anti-bcma car bcma-directed car bcma-directed car bcma-targeted car human gene therapy cell therapy recipients van de donk anti-fcrh5/cd3 memory stem cells cancer metastasis access targeted mass spectrometry major cancer center

Schema {🗺️}

WebPage:
      mainEntity:
         headline:CAR T-cell therapy to treat multiple myeloma: current state and future directions
         description:Chimeric antigen receptor (CAR) T-cell therapy represents a transformative advancement in treating relapsed or refractory multiple myeloma (MM) in both early- and late-line settings. MM, a plasma cell malignancy, traditionally requires ongoing complex drug regimens, posing significant burdens on patients. In contrast, CAR T-cell therapy offers a one-time treatment option without the need for continuous maintenance therapy. CAR T-cell therapy leverages engineered T-cells to target specific antigens on tumor cells, leading to their elimination. Current approved therapies target B-cell maturation antigen (BCMA); new targets are under investigation, such as G-protein-coupled receptor class C group 5 member D (GPRC5D). Despite its efficacy, CAR T-cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS), necessitating careful management. The review will provide an overview of the design and manufacturing of CAR T-cells and current FDA indications, as well as challenges and future directions of CAR-T therapy for MM treatment.
         datePublished:2024-12-03T00:00:00Z
         dateModified:2024-12-03T00:00:00Z
         pageStart:1
         pageEnd:12
         sameAs:https://doi.org/10.1007/s10555-024-10219-1
         keywords:
            CAR T
            Cell therapy, Indication of CAR T
            Cells, Toxicities of CAR T
            Cells, Resistance mechanisms of CAR T
            Cells
            Cancer Research
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-024-10219-1/MediaObjects/10555_2024_10219_Fig1_HTML.png
         isPartOf:
            name:Cancer and Metastasis Reviews
            issn:
               1573-7233
               0167-7659
            volumeNumber:44
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Siddhartha Thammineni Reddy
               affiliation:
                     name:Stanford University
                     address:
                        name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
                        type:PostalAddress
                     type:Organization
                     name:Hackensack University Medical Center
                     address:
                        name:Hackensack University Medical Center, NJ, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Hitomi Hosoya
               affiliation:
                     name:Stanford University
                     address:
                        name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lekha Mikkilineni
               affiliation:
                     name:Stanford University
                     address:
                        name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:CAR T-cell therapy to treat multiple myeloma: current state and future directions
      description:Chimeric antigen receptor (CAR) T-cell therapy represents a transformative advancement in treating relapsed or refractory multiple myeloma (MM) in both early- and late-line settings. MM, a plasma cell malignancy, traditionally requires ongoing complex drug regimens, posing significant burdens on patients. In contrast, CAR T-cell therapy offers a one-time treatment option without the need for continuous maintenance therapy. CAR T-cell therapy leverages engineered T-cells to target specific antigens on tumor cells, leading to their elimination. Current approved therapies target B-cell maturation antigen (BCMA); new targets are under investigation, such as G-protein-coupled receptor class C group 5 member D (GPRC5D). Despite its efficacy, CAR T-cell therapy is associated with serious toxicities such as cytokine release syndrome (CRS) and immune-effector cell-associated neurotoxicity syndrome (ICANS), necessitating careful management. The review will provide an overview of the design and manufacturing of CAR T-cells and current FDA indications, as well as challenges and future directions of CAR-T therapy for MM treatment.
      datePublished:2024-12-03T00:00:00Z
      dateModified:2024-12-03T00:00:00Z
      pageStart:1
      pageEnd:12
      sameAs:https://doi.org/10.1007/s10555-024-10219-1
      keywords:
         CAR T
         Cell therapy, Indication of CAR T
         Cells, Toxicities of CAR T
         Cells, Resistance mechanisms of CAR T
         Cells
         Cancer Research
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10555-024-10219-1/MediaObjects/10555_2024_10219_Fig1_HTML.png
      isPartOf:
         name:Cancer and Metastasis Reviews
         issn:
            1573-7233
            0167-7659
         volumeNumber:44
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Siddhartha Thammineni Reddy
            affiliation:
                  name:Stanford University
                  address:
                     name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
                     type:PostalAddress
                  type:Organization
                  name:Hackensack University Medical Center
                  address:
                     name:Hackensack University Medical Center, NJ, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Hitomi Hosoya
            affiliation:
                  name:Stanford University
                  address:
                     name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lekha Mikkilineni
            affiliation:
                  name:Stanford University
                  address:
                     name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer and Metastasis Reviews
      issn:
         1573-7233
         0167-7659
      volumeNumber:44
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Stanford University
      address:
         name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
         type:PostalAddress
      name:Hackensack University Medical Center
      address:
         name:Hackensack University Medical Center, NJ, USA
         type:PostalAddress
      name:Stanford University
      address:
         name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
         type:PostalAddress
      name:Stanford University
      address:
         name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Siddhartha Thammineni Reddy
      affiliation:
            name:Stanford University
            address:
               name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
               type:PostalAddress
            type:Organization
            name:Hackensack University Medical Center
            address:
               name:Hackensack University Medical Center, NJ, USA
               type:PostalAddress
            type:Organization
      name:Hitomi Hosoya
      affiliation:
            name:Stanford University
            address:
               name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
               type:PostalAddress
            type:Organization
      name:Lekha Mikkilineni
      affiliation:
            name:Stanford University
            address:
               name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
      name:Hackensack University Medical Center, NJ, USA
      name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
      name:Division of Bone and Marrow Transplantation & Cellular Therapies, Stanford University, Palo Alto, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(450)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5s.

LINK . SPRINGER . COM {}